- Home
- INTS vs IBIO Comparison
INTS vs IBIO Comparison
Compare INTS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- IBIO
- Stock Information
- Founded
- INTS 2012
- IBIO 2008
- Country
- INTS United States
- IBIO United States
- Employees
- INTS N/A
- IBIO N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- IBIO Health Care
- Exchange
- INTS Nasdaq
- IBIO Nasdaq
- Market Cap
- INTS 10.9M
- IBIO 11.9M
- IPO Year
- INTS 2023
- IBIO N/A
- Fundamental
- Price
- INTS $0.24
- IBIO $0.87
- Analyst Decision
- INTS Strong Buy
- IBIO Strong Buy
- Analyst Count
- INTS 4
- IBIO 2
- Target Price
- INTS $4.50
- IBIO $5.50
- AVG Volume (30 Days)
- INTS 3.9M
- IBIO 1.9M
- Earning Date
- INTS 11-12-2025
- IBIO 11-11-2025
- Dividend Yield
- INTS N/A
- IBIO N/A
- EPS Growth
- INTS N/A
- IBIO N/A
- EPS
- INTS N/A
- IBIO N/A
- Revenue
- INTS N/A
- IBIO $400,000.00
- Revenue This Year
- INTS N/A
- IBIO N/A
- Revenue Next Year
- INTS N/A
- IBIO N/A
- P/E Ratio
- INTS N/A
- IBIO N/A
- Revenue Growth
- INTS N/A
- IBIO 77.78
- 52 Week Low
- INTS $0.19
- IBIO $0.56
- 52 Week High
- INTS $4.18
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- INTS 36.68
- IBIO 55.70
- Support Level
- INTS $0.22
- IBIO $0.83
- Resistance Level
- INTS $0.25
- IBIO $0.97
- Average True Range (ATR)
- INTS 0.02
- IBIO 0.06
- MACD
- INTS -0.00
- IBIO -0.00
- Stochastic Oscillator
- INTS 29.27
- IBIO 50.00
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.